Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction
| Autor: | Takashi Nakamura, Masafumi Watanabe, Ken Watanabe, Yoichiro Otaki, Takanori Arimoto, Satoshi Nishiyama, Tetsu Watanabe, Shigehiko Kato, Harutoshi Tamura, Tetsuro Shishido, Hiroki Takahashi, Takayo Murase |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty Multivariate analysis Xanthine oxidoreductase Xanthine Dehydrogenase Hyperuricemia 030204 cardiovascular system & hematology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Original Research Articles Internal medicine Humans Medicine Original Research Article 030212 general & internal medicine Heart Failure chemistry.chemical_classification Reactive oxygen species business.industry Proportional hazards model Confounding Stroke Volume medicine.disease Pathophysiology Uric Acid Heart failure with preserved ejection fraction chemistry lcsh:RC666-701 Heart failure Cardiology Uric acid Cardiology and Cardiovascular Medicine business |
| Zdroj: | ESC Heart Failure, Vol 7, Iss 4, Pp 1735-1743 (2020) ESC Heart Failure |
| ISSN: | 2055-5822 |
| Popis: | Aims Reactive oxygen species are reportedly involved in the mechanism underlying heart failure with preserved ejection fraction (HFpEF); however, the disease pathophysiology remains poorly understood. Xanthine oxidoreductase (XOR), the rate‐limiting enzyme of purine metabolism, plays an important role in uric acid production and generates reactive oxygen species. However, the impact of plasma XOR activity on the clinical outcomes of patients with HFpEF remains unclear. The aim of this study was to investigate whether plasma XOR activity is associated with major adverse cardiovascular events (MACEs) in patients with HFpEF. Methods and results The plasma XOR activity was measured in 257 patients with HFpEF, who were then divided into three groups according to the activity levels: low XOR group (120 pmol/h/mL, n = 52). During the median follow‐up period of 809 days, there were 74 MACEs. Kaplan–Meier analysis revealed that the high XOR group was at the highest risk for MACEs. Multivariate analysis by Cox's proportional hazard regression approach showed that high XOR activity was significantly associated with MACEs, after adjustment for confounding factors. The patients were also divided into four groups according to the absence/presence of high XOR activity and/or hyperuricaemia. According to the multivariate Cox regression analysis, high XOR activity was associated with MACEs, regardless of the hyperuricaemia status. Conclusions Elevated plasma XOR activity is significantly associated with adverse clinical outcomes in patients with HFpEF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text